The Trump administration is moving forward with plans to make certain peptide injections more widely available in the United States, despite concerns about their safety and effectiveness. The News International, citing The Associated Press, reports that Health Secretary Robert F. Kennedy Jr.'s department has submitted an interim policy to the White House that could allow specialist pharmacies to produce some currently restricted peptides.

The proposal, now under review, could include BPC-157, a substance promoted for muscle growth and injury recovery. Peptides are compounds involved in several bodily functions, including growth and metabolism, and while some appear in approved medicines, many of the injections pushed by wellness influencers have not undergone sufficient human testing.

Why BPC-157 was restricted

The Food and Drug Administration previously restricted BPC-157 and several other peptides because of potential risks, including contamination, allergic reactions and tumor growth. That is a specific list, and it is worth noticing that two of those three risks are about what is in the vial rather than what the molecule does.

The argument for loosening

Kennedy has argued that letting pharmacies produce these substances could reduce demand for unregulated products sold online. It is a harm-reduction case rather than an efficacy case, and the distinction matters: nothing in the proposal turns on new evidence that these peptides work.

The split inside the agency

In July, external FDA advisers recommended easing restrictions on six peptides, despite objections from agency scientists. An advisory panel overruling the staff scientists is the most interesting detail in this story, and it is the one most likely to shape how the final policy is read.

What the policy would actually do

The proposed rule would temporarily allow certain pharmacies to produce peptides without facing enforcement action. That is enforcement discretion, not approval: the compounds would not become FDA-approved drugs, and the contamination and allergic reaction concerns the agency cited do not disappear because a compounding pharmacy is making the vial.

Where this leaves BPC-157

The policy is still under White House review, and the reporting does not say when or whether it will take effect. What remains unsettled is the part the proposal never addressed: whether the peptides on the list have been tested enough in humans to justify the demand they already have.